Pepinemab
- Generic Name
- Pepinemab
- Drug Type
- Biotech
- CAS Number
- 2097151-87-4
- Unique Ingredient Identifier
- BPZ4A29SYE
- Background
Pepinemab is under investigation in clinical trial NCT03769155 (VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma).
Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer
- Conditions
- HER2-positive Breast Cancer
- Interventions
- First Posted Date
- 2022-05-18
- Last Posted Date
- 2025-03-13
- Target Recruit Count
- 28
- Registration Number
- NCT05378464
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
- Conditions
- Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)
- Interventions
- First Posted Date
- 2021-03-25
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Vaccinex Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT04815720
- Locations
- 🇺🇸
Highlands Oncology Group, PA - North Hills, Springdale, Arkansas, United States
🇺🇸California Cancer Associates for Research and Excellence (CCARE)-Fresno, Fresno, California, United States
🇺🇸UCSF Medical Center at Mission Bay, San Francisco, California, United States
SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD)
- First Posted Date
- 2020-05-08
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Vaccinex Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT04381468
- Locations
- 🇺🇸
University of Rochester Medical Center, Rochester, New York, United States
🇺🇸Indiana University School of Medicine, Indianapolis, Indiana, United States
🇺🇸JEM Research Institute, Lake Worth, Florida, United States
VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma
- Conditions
- Pathologic Stage IIID Cutaneous Melanoma AJCC v8Pathologic Stage IIIB Cutaneous Melanoma AJCC v8Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
- Interventions
- First Posted Date
- 2018-12-07
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Emory University
- Target Recruit Count
- 41
- Registration Number
- NCT03769155
- Locations
- 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
VX15/2503 in Combination with Ipilimumab or Nivolumab in Patients with Head and Neck Cancer
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- First Posted Date
- 2018-10-01
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Emory University
- Target Recruit Count
- 50
- Registration Number
- NCT03690986
- Locations
- 🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer
- First Posted Date
- 2017-08-31
- Last Posted Date
- 2022-05-02
- Lead Sponsor
- Vaccinex Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT03268057
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸University of California Los Angeles (UCLA), Los Angeles, California, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of Pepi
- First Posted Date
- 2015-06-25
- Last Posted Date
- 2022-05-02
- Lead Sponsor
- Vaccinex Inc.
- Target Recruit Count
- 301
- Registration Number
- NCT02481674
- Locations
- 🇺🇸
University of Vermont, Burlington, Vermont, United States
🇺🇸University of California, San Diego, La Jolla, California, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS
- First Posted Date
- 2013-01-10
- Last Posted Date
- 2015-02-06
- Lead Sponsor
- Vaccinex Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT01764737
- Locations
- 🇺🇸
Wayne State University - University Health Center, Detroit, Michigan, United States
🇺🇸University of Colorado Hospital, Aschutz Inpatient Pavilion, Aurora, Colorado, United States
🇺🇸North Central Neurology Associates, PC, Cullman, Alabama, United States
Evaluation of Safety, Tolerability, PK & PD of Intravenous VX15/2503 in Patients With Advanced Solid Tumors
- First Posted Date
- 2011-03-11
- Last Posted Date
- 2014-08-13
- Lead Sponsor
- Vaccinex Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT01313065
- Locations
- 🇺🇸
South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States
🇺🇸Virginia G. Piper Cancer Center at Scottsdale Healthcare, Scottsdale, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.